For the Quarter Ending March 2026
Orlistat Prices in North America
- In United States, the Orlistat Price Index rose quarter-over-quarter in Q1 2026, driven by elevated production costs.
- The Orlistat Production Cost Trend increased in March 2026 as producer prices rose 4.0% year-over-year.
- Retail sales grew 4.0% year-over-year in March 2026, while consumer inflation reached 3.3%, impacting pharmacy pricing.
- The Orlistat Demand Outlook strengthened in March 2026, supported by 4.3% unemployment and 91.8 consumer confidence.
- Industrial production grew 0.7% year-over-year in March 2026, and the Manufacturing Index expanded, ensuring supply stability.
- Soybean meal fermentation feedstock costs for Orlistat strengthened in February 2026, directly elevating synthesis expenses.
- United States soybean fermentation feedstock inventories stabilized in March 2026, while import volumes strengthened simultaneously.
- Soybean meal fermentation feedstock export volumes surged in February 2026, alongside strengthening domestic feed consumption.
- The Orlistat Price Forecast reflected an upward trajectory throughout Q1 2026 due to sustained cost-push dynamics.
Why did the price of Orlistat change in March 2026 in North America?
- Producer prices rose 4.0% year-over-year in March 2026, directly increasing active pharmaceutical ingredient synthesis expenses.
- Soybean meal fermentation feedstock costs strengthened in February 2026, adding significant pressure to manufacturing operations.
- Retail sales grew 4.0% year-over-year in March 2026, sustaining robust consumer purchasing power at pharmacies.
Orlistat Prices in APAC
- In China, the Orlistat Price Index rose quarter-over-quarter in Q1 2026, driven by strengthening feedstock costs.
- A mild Consumer Price Index increase of 1.0% in March 2026 supported a steady Orlistat Demand Outlook.
- The Producer Price Index rose 0.5% in March 2026, directly elevating the Orlistat Production Cost Trend.
- Industrial production grew 5.7% in March 2026, ensuring robust supply availability for the pharmaceutical manufacturing sector.
- Retail sales grew 1.7% and unemployment reached 5.4% in March 2026, dampening consumer discretionary spending.
- The consumer confidence index hit 91.6 in February 2026, negatively impacting the OTC weight-loss medication market.
- The Manufacturing Index expanded in March 2026, indicating healthy production rates for fine chemical precursors.
- The Orlistat Price Forecast reflected upward pressures from strengthened soybean meal fermentation feedstock costs in Q1 2026.
- Healthcare reforms and rising obesity rates bolstered prescription weight management drug adoption throughout Q1 2026.
Why did the price of Orlistat change in March 2026 in APAC?
- Imported soybean meal fermentation feedstock costs strengthened due to higher freight expenses in Q1 2026.
- The Producer Price Index rose 0.5% in March 2026, increasing factory-gate prices for chemical precursors.
- Broader energy costs and transportation logistics expenses surged significantly amid geopolitical tensions in Q1 2026.
Orlistat Prices in Europe
- In Germany, the Orlistat Price Index rose quarter-over-quarter in Q1 2026, driven by surging pharmaceutical manufacturing costs.
- The Orlistat Production Cost Trend increased during March 2026 as the CPI rose by 2.7% year-over-year.
- Despite the overall PPI declining 0.2% in March 2026, pharmaceutical manufacturing producer prices surged in February 2026.
- Industrial production remained flat at 0.0% in February 2026, while overall pharmaceutical production growth decelerated in January 2026.
- Retail sales contracted 2.0% in March 2026, yet the Orlistat Demand Outlook expanded robustly throughout Q1 2026.
- The unemployment rate held at 4.0% in February 2026, while consumer confidence dropped to -13.9 points in March 2026.
- The Manufacturing Index expanded in March 2026, and soybean and glycerine feedstock costs stabilized during Q1 2026.
- Pharmaceutical export flows tightened in Q1 2026, which influenced the upward Orlistat Price Forecast during March 2026.
Why did the price of Orlistat change in March 2026 in Europe?
- Regional demand for anti-obesity medications expanded during Q1 2026, driving strong upward market pricing pressure.
- Pharmaceutical manufacturing producer prices surged in February 2026, directly elevating the overall production cost burdens.
- Crude oil benchmarks strengthened in January 2026, impacting the broader chemical logistics and transportation expenses.
For the Quarter Ending December 2025
Orlistat Prices in North America
- In United States, Orlistat Price Index rose in Q4 2025, driven by increased production costs.
- Orlistat production costs increased in Q4 2025, as industrial electricity costs rose in November 2025.
- Rising input costs for the pharmaceutical sector were indicated by a 3.0% year-over-year PPI increase in November 2025.
- General inflation, with a 2.7% year-over-year CPI increase in December 2025, raised raw material costs.
- Orlistat demand outlook was supported by a 3.3% year-over-year increase in retail sales in November 2025.
- Consumer spending on health products was bolstered by a 4.4% unemployment rate in December 2025.
- A 2.0% year-over-year increase in industrial production in December 2025 indirectly supported Orlistat supply chains.
- Orlistat price trends in Q4 2025 reflected ongoing inflationary pressures and robust consumer demand.
Why did the price of Orlistat change in December 2025 in North America?
- Rising input costs, with a 2.7% year-over-year CPI increase in December 2025, elevated production expenses.
- Strong consumer spending, supported by a 4.4% unemployment rate in December 2025, boosted Orlistat demand.
- Natural gas spot prices gradually rose in December 2025, contributing to increased energy feedstock costs.
Orlistat Prices in APAC
- In China, the Orlistat Price Index fell quarter-over-quarter in Q4 2025, influenced by weak consumer demand.
- Orlistat production costs declined in December 2025, as producer prices fell by 1.9% year-over-year.
- The Manufacturing Index expanded in December 2025, supporting a robust supply chain for Orlistat production.
- Industrial production grew by 5.2% year-over-year in December 2025, ensuring stable raw material supply for Orlistat.
- Orlistat demand outlook was subdued in Q4 2025 due to decelerated economic growth and 0.9% retail sales growth.
- New chemical capacity emerged in China in 2025, intensifying competition and impacting Orlistat pricing.
- Demand for pharmaceutical products, particularly weight management, showed expansion in China in 2025.
- Consumer sentiment cooled in Q4 2025, contributing to cautious spending on discretionary health products.
Why did the price of Orlistat change in December 2025 in APAC?
- Producer prices declined by 1.9% year-over-year in December 2025, reducing Orlistat manufacturing costs.
- Weak consumer demand, with 0.8% CPI and 0.9% retail sales growth in December 2025, pressured Orlistat prices.
- New chemical capacity and persistent overcapacity in the broader chemical sector intensified competition in 2025.
Orlistat Prices in Europe
- In Germany, the Orlistat Price Index remained stable quarter-over-quarter in Q4 2025, supported by 1.8% CPI in December 2025.
- Orlistat production costs declined in December 2025, as producer prices fell by 2.5% year-over-year.
- Industrial energy and natural gas prices for industrial customers weakened in Germany during December 2025.
- Orlistat demand outlook faced challenges in December 2025 due to a contracting Manufacturing Index.
- Consumer confidence at -17.5 in December 2025 impacted discretionary OTC Orlistat spending.
- Retail sales grew by 1.1% year-over-year in November 2025, offering some support for OTC Orlistat demand.
- The unemployment rate of 6.2% in December 2025 reduced consumer purchasing power for health products.
- Germany's pharmaceutical market experienced moderate growth in 2025, supporting overall Orlistat demand.
- Trade barriers, including US tariff policy, negatively impacted German chemical companies' US business in 2025.
- Orlistat Price Index forecast suggests continued stability, balancing lower costs with cautious consumer spending.
Why did the price of Orlistat change in December 2025 in Europe?
- Producer prices decreased by 2.5% year-over-year in December 2025, reducing Orlistat manufacturing costs.
- Consumer confidence at -17.5 in December 2025 dampened demand for discretionary OTC Orlistat.
- Industrial energy and natural gas prices weakened in Germany during December 2025, lowering operational expenses.
For the Quarter Ending September 2025
Orlistat Prices in North America
- In United States, the Orlistat Price Index remained stable quarter-over-quarter in Q3 2025, balancing demand and cost factors.
- Orlistat production costs faced upward pressure from a 2.6% PPI increase in August 2025 for manufacturing inputs.
- Hexane feedstock costs moved lower in Q3 2025, driven by consistent refining operations and softened downstream intake.
- Demand for weight-loss drugs, including GLP-1 analogues, showed significant growth in 2025, supporting Orlistat market.
- Robust US retail sales, up 5.42% in September 2025, bolstered consumer spending despite weakened consumer confidence.
- A low 4.3% unemployment rate in September 2025 supported disposable income and access to health insurance.
- The global chemicals industry experienced tight margins and overcapacity in Q3 2025, affecting overall market dynamics.
- US chemical production contracted in Q3 2025, reflecting broader industrial sluggishness with minimal industrial production growth.
- Orlistat Price Forecast suggests continued stability, balancing cost pressures with sustained demand for weight management solutions.
Why did the price of Orlistat change in September 2025 in North America?
- Producer prices increased 2.6% in August 2025, raising Orlistat manufacturing input costs.
- Robust US retail sales, up 5.42% in September 2025, supported demand for health products.
- Hexane feedstock costs declined in Q3 2025, partially offsetting other production cost increases.
Orlistat Prices in APAC
- In China, the Orlistat Price Index fell quarter-over-quarter, influenced by deflationary pressures and global oversupply in Q3 2025.
- Orlistat production costs were influenced by falling factory-gate prices (PPI -2.3% YoY) and steady petrochemical feedstock costs.
- Domestic pharmaceutical demand strengthened in Q3 2025, driven by an aging population and increasing chronic diseases.
- Overall domestic consumption showed weakness in Q3 2025, despite 3.0% year-on-year retail sales growth.
- China's industrial production increased 6.5% year-on-year in September 2025, supporting stable supply chains.
- The Manufacturing Index was contracting in September 2025, indicating a slowdown in broader industrial activity.
- Consumer confidence stood at 89.6 in September 2025, reflecting pessimism and reduced discretionary spending.
- Global oversupply in the chemicals market persisted in Q3 2025, with China adding significant chemical capacity.
- The pharmaceutical intermediate sector in China expanded steadily in Q3 2025, driven by cost-effective manufacturing.
Why did the price of Orlistat change in September 2025 in APAC?
- Deflationary pressures (CPI -0.3% YoY September 2025) dampened consumer purchasing power.
- A contracting Manufacturing Index in September 2025 signaled economic weakness and impacted supply chains.
- Global oversupply in the chemicals market, coupled with China's capacity additions, exerted downward pressure.
Orlistat Prices in Europe
- In Germany, the Orlistat Price Index fell quarter-over-quarter in Q3 2025, influenced by a 1.7% decline in producer prices.
- Orlistat production costs in Q3 2025 saw mixed trends from eased natural gas, but elevated electricity and carbon costs.
- Orlistat demand outlook in Q3 2025 was tempered by significantly negative consumer confidence (-23.6 index).
- A contracting Manufacturing Index and 1.0% industrial production decline in September 2025 impacted Orlistat supply.
- Low unemployment (3.9%) in September 2025 supported Orlistat demand by bolstering consumer purchasing power.
- Germany's pharmaceutical market expanded in Q3 2025, providing a stable demand base for Orlistat.
- Rising CPI (2.4%) in September 2025 signaled higher operational costs for Orlistat producers.
- Modest retail sales growth (0.8%) in September 2025 indicated cautious spending on discretionary Orlistat.
Why did the price of Orlistat change in September 2025 in Europe?
- Producer prices (PPI) declined by 1.7% in September 2025, reducing Orlistat input costs.
- Consumer confidence was significantly negative (-23.6 index) in September 2025, dampening Orlistat demand.
- Elevated electricity prices for businesses in Q3 2025 increased Orlistat manufacturing operational costs.
